Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104 Alessandra CesanoSophie VisonneauD. Santoli ORIGINAL ARTICLE Pages: 125 - 136
Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma John M. KirkwoodJohn WilsonRonald B. Herberman ORIGINAL ARTICLE Pages: 137 - 149
Oligoclonal in vitro response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients Sonja FischerArmin SchefflerD. Kabelitz ORIGINAL ARTICLE Pages: 150 - 156
Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma P. WersällI. OhlssonJ. Boethius ORIGINAL ARTICLE Pages: 157 - 164
Role of macrophage-colony-stimulating factor in regulating the accumulation and phenotype of tumor-associated macrophages S. T. DoughertyConnie J. EavesGraeme J. Dougherty ORIGINAL ARTICLE Pages: 165 - 172
Postural effects on peritoneal transport and systemic uptake of radiolabeled monoclonal antibodies Jeffrey S. BarrettSusan J. FisherR. L. Wahl ORIGINAL ARTICLE Pages: 173 - 178
Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22 Robert M. SharkeyThomas M. BehrD. M. Goldenberg ORIGINAL ARTICLE Pages: 179 - 188